Myelin Basic Protein Binding Agents for Neurological Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for visualizing myelin in the nervous system, such as retrograde labeling and existing dyes, face challenges like ambiguity in signal interpretation, limited ability to cross the blood-brain barrier, and inefficiencies in nerve visualization, particularly in diagnosing and treating myelin-associated neuropathies like multiple sclerosis.
Innovation Solution
Development of agents that specifically bind to myelin basic protein, including compounds of Formula I, their 13C enriched, 19F-labeled, or radioisotope derivatives, which are administered to enhance myelin visualization by specifically targeting myelin in the nervous system, allowing for improved diagnostic and treatment tools.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If retrograde labeling is used to visualize nerves, then nerve visualization is achieved, but the signal is ambiguous and requires long times for retrograde transport
Solution Approach 1:
The invention segments the visualization approach by using specific fluorescent dyes (BMB and BDB) that selectively bind to myelin basic protein, separating the visualization function from the retrograde transport process. This allows direct imaging of myelin without requiring complete retrograde transport of contrast agents.
Solution Approach 2:
The patent introduces myelin basic protein as an intermediary target. The fluorescent dyes bind specifically to MBP, which is abundant in myelin sheaths, serving as a mediator that enables direct visualization of myelin structure without requiring retrograde transport of the imaging agent itself.
2Reliability
If existing dyes are used for myelin visualization, then some myelin labeling is achieved, but most dyes cannot cross the blood-brain or blood-nerve barrier
Solution Approach 1:
The patent modifies the chemical parameters of the dye molecules (BMB and BDB) to achieve optimal balance between barrier penetration capability and specific binding affinity to myelin basic protein. The molecular structure is optimized to allow sufficient crossing of biological barriers while maintaining high specificity for MBP.
3Measurement precision
If commercially available FluoroMyelin dyes are used, then myelin identification is possible, but the dyes have limited ability to cross biological barriers and show non-specific binding
Solution Approach 1:
The invention enhances local quality by designing dyes with specific molecular characteristics that preferentially interact with myelin basic protein in myelin sheaths. The dyes exhibit high local concentration and specific binding at the target site (myelin) while minimizing non-specific binding in surrounding tissues through optimized chemical structure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These agents provide enhanced visualization of myelin, enabling more accurate diagnosis and treatment of myelin-associated neuropathies by specifically binding to myelin basic protein, improving contrast and reducing non-specific binding, thus aiding in the identification and monitoring of myelin-related conditions.
Implementation Method 1
administering to a subject an agent that binds specifically to myelin basic protein
Data Source
Figure 1A~1B
Figure 2
Figure 3
AI summary
The present invention relates to methods for myelin basic protein detection comprises identifying a subject at risk of or diagnosed with a myelin-associated neuropathy, parenterally administering to the subject the agent, and determining myelination in the subject by detecting binding to myelin basic protein. Methods for the detection of myelin and a quantitative measurement of its local concentration in a sample using an agent with specific binding to myelin basic protein are also provided as is a kit containing the agent or its derivatives for use in detecting myelin basic protein.